Article thumbnail

The role of lifestyle changes in the management of chronic liver disease

By Valerio Nobili, Christine Carter-Kent and Ariel E Feldstein

Abstract

The prevalence of obesity worldwide has dramatically increased during the last three decades. With obesity comes a variety of adverse health outcomes which are grouped under the umbrella of metabolic syndrome. The liver in particular seems to be significantly impacted by fat deposition in the presence of obesity. In this article we discuss several liver conditions which are directly affected by overweight and obese status, including non-alcoholic fatty liver disease, chronic infection with hepatitis C virus and post-liver transplant status. The deleterious effects of obesity on liver disease and overall health can be significantly impacted by a culture that fosters sustained nutritional improvement and regular physical activity. Here we summarize the current evidence supporting non-pharmacological, lifestyle interventions that lead to weight reduction, improved physical activity and better nutrition as part of the management and treatment of these liver conditions

Topics: Review
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:3127780
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2010). A: Diabetes mellitus increases the risk of mortality following liver transplantation independent of MELD score. Dig Dis Sci
  2. (2009). Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology
  3. (2008). Almeida CG, de Freitas LA: Nonalcoholic fatty liver disease in severely obese individuals: The influence of bariatric surgery. Ann Hepatol
  4. (2006). Behling C: Prevalence of fatty liver in children and adolescents. Pediatrics
  5. (2009). BH: The relation between non-alcoholic fatty liver disease and the risk of coronary heart disease in Koreans.
  6. (2009). Eason JD: Effects of obesity, diabetes, and prior abdominal surgery on resource utilization in liver transplantation: a single-center study. Liver Transpl
  7. (2002). EE: Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut
  8. (2009). Effects of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors.
  9. (2009). Fujimoto K: A pilot trial of body weight reduction for nonalcoholic fatty liver disease with a home-based lifestyle modification intervention delivered in collaboration with interdisciplinary medical staff.
  10. (2009). Ghany MG: Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology
  11. (2004). Grundy SM, Hobbs HH: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology
  12. (2003). High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology
  13. (2008). High prevalence of metabolic syndrome and long-term survival after liver transplantation.
  14. (2005). Insulin resistance impairs sustained viral response rate to peginteferon plus ribavirin in chronic hepatitis C patients. Gastroenterology
  15. (2003). Insulin resistance syndrome and nonalcoholic fatty liver disease. Endocr Pract
  16. (2003). JR: In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy.
  17. (2008). Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology
  18. (2005). Lok AS: One-year intense nutritional counseling results in histological improvement in patients with nonalcoholic steatohepatitis: a pilot study.
  19. (2004). Marchesini G: Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obesity Rev
  20. (2008). Metabolic syndrome in liver transplantation: relation to etiology and immunosupression. Liver Transplantation
  21. (2004). Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin and quality of life. Gut
  22. (2008). Negro F: Pioglitazone in chronic hepatitis C not responding to pegylated interferon alpha and ribavirin.
  23. (2008). Nuutila P: Effect of weight loss on liver free fatty acid uptake and hepatic insulin resistance.
  24. (2009). Pattou F: Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology
  25. (2009). Pediatric nonalcoholic fatty liver disease: preventive and therapeutic value of lifestyle intervention.
  26. (2007). Peltekian KM: Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl
  27. (2000). Persing DH: Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol or cholestatic disease.
  28. (1997). Rubino A: Liver involvement in obese children. Digestive Dis Sci
  29. (2004). Sanyal AJ: Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clin Liver Dis
  30. (2001). Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology
  31. (1997). Sujaku K: Therapeutic effects of restricted diet and exercise in obese patients with fatty liver.
  32. (2007). T: Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease.
  33. (2000). Thomas DL: Prevalence of type 2 diabetes mellitus among persons with hepatitis C infection in the United States. Ann Intern Med
  34. (2009). Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginteferon alfa-2a plus metformin. Hepatology
  35. (2010). Wing RR: Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology
  36. World Health Organization Initiative for Vaccine Research. Hepatitis C.
  37. (2010). Younossi ZM: Nutritional assessments of patients with nonalcoholic fatty liver disease. Obesity Surg
  38. (2008). Zein NN: Clinical Significance of metabolic syndrome in the setting of chronic hepatitis C infection. Clin Gastroenterol Hepatol